|
633. |
Siebenhaar, F.+, Sofi, S., Neisinger, S., Akin, C., Pyatilova, P., Grekowitz, E., Haendel, A., Hawro, T., Kiefer, L., Magerl, M., Metz, M., Maurer, M., and Weller, K.: The mastocytosis control test: a patient-reported outcome measure assessing disease control. J. Allergy Clin. Immunol. Pract. 2025: 13; 647-657. IF: TBD (IF 2024: 6.60) |
o.633
|
632. |
Giménez-Arnau, A. M.+, Balp, M.-M., Danyliv, A., Winders, T., O’Donoghue, J., Kleebach, J., Morrison, S., Walsh, S., Mueller, M., Lopez-Ortiz, D., Maurer, M., and Bernstein, J. A.: Assessing preferences of patients with chronic spontaneous urticaria for injectable treatment profiles. Patient 2025: 18; 173-185. IF: TBD (IF 2024: 3.10) |
o.632
|
631. |
Soegiharto, R.+, Alizadeh Aghdam, M., Sørensen, J. A., van Lindonk, E., Bulut Demir, F., Mohammad Porras, N., Matsuo, Y., Kiefer ,L., Knulst, A. C., Maurer, M., Ritchie, C., Rudenko, M., Kocatürk, E., Criado, R. F. J., Gregoriou, S., Bobylev, T., Kleinheinz, A., Takahagi, S., Hide, M., Giménez-Arnau, A. M., Salman, A., Kara, R. O., Dikicier, B. S., van Doorn M. B. A., Thomsen, S. F., van den Reek, J. M. P. A., and Röckman, H.: Omalizumab is effective and safe in chronic inducible urticaria (CIndU): real-world data from a large multi-national UCARE study. Allergy 2025: 80; 489-499. IF: TBD (IF 2024: 12.00) |
o.631
|
630. |
Jiao, Q.+, Lohse, K., Rauber-Ellinghaus, M. M., Kolkhir, P., Frischbutter, S., Scheffel, J., Xiang, Y.-K., Maurer, M.+, and Altrichter, S.: Basophil and eosinophil recruitment to skin lesions is linked to features of autoimmune chronic spontaneous urticaria including basopenia. J. Eur. Acad. Dermatol. Venereol. 2025: 39; e155-e157. IF: TBD (IF 2024: 8.00) |
o.630
|
629. |
Rastgoo, S., Mohammadi, M., Maurer, M., Atabaki, M., Tavakkol-Afshari, J., and Khoshkhui, M.+: Expression of STAT3, IL-27p28, and IL12p35 is deregulated and linked to autoimmune markers in chronic spontaneous urticaria. Clin. Exp. Dermatol. 2025: 50; 357-364. IF: TBD (IF 2024: 2.80) |
o.629
|
628. |
Schnarkowski, P., Salamah, P., Grekowitz, E., Terhorst-Molawi, D., Maurer, M., Weller, K., and Altrichter, S.+: Validation of the cholinergic urticaria activity score, CholUAS. J. Allergy Clin. Immunol. Pract. 2025: 13; 213-219. IF: TBD (IF 2024: 6.60) |
o.628
Validation of the cholinergic urticaria activity score, CholUAS Read More »
|
627. |
Neisinger, S.+, Salameh, P., Gutsche, A., Aulenbacher, F., Siebenhaar, F., and Maurer, M.: Disease control and quality of life in chronic spontaneous urticaria and recurrent angioedema are strongly linked, but not in all patients. Clin. Transl. Allergy 2025: 15; e70026. IF: TBD (IF 2024: 4.00) |
o.627
|
626. |
Shurmelova, I., Baldyga, A., Grekowitz, E., Kimeswenger, S., Hoetzenecker, W., Maurer, M.+, and Altrichter, S.+: Skin reaction patterns in cholinergic urticaria. Allergol. Int. 2025: 1; 115-125. IF: TBD (IF 2024: 6.70) |
o.626
Skin reaction patterns in cholinergic urticaria Read More »
|
625. |
Muñoz, M.+, Schoepke, N., Altrichter, S., Staubach, P., Geppert-Steidl, C., Durner, L., Bernstein, J. A., Maurer, M., and Weller, K.: Development of the symptomatic dermographism quality of life questionnaire. Clin. Transl. Allergy 2025: 15; e70038. IF: TBD (IF 2024: 4.00) |
o.625
Development of the symptomatic dermographism quality of life questionnaire Read More »
|
624. |
Maurer, M., Cimbollek, S., Kelly, M., Rodney, K., Elliott, J., LoboGuerrero, E., and Magerl, M.+: Real-world evidence of the effectiveness and utilization of subcutaneous C1INH long-term prophylaxis in patients with HAE in Spain and Germany. Front. Immunol. 2025: 16; 1576235. IF: TBD (IF 2024: 5.90) |
o.624